{"id":"dexlansoprazole-delayed-release-capsules","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":["diarrhea","abdominal pain","nausea","upper respiratory tract infection","vomiting","flatulence"],"contraindications":["hypersensitivity to dexlansoprazole or any component of the formulation","hypersensitivity to substituted benzimidazoles","concomitant use with rilpivirine-containing products"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT02064907"],"aliases":["Dexilant"],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"","brandName":"Dexlansoprazole Delayed Release Capsules","companyId":"takeda","mechanism":{"target":"H+/K+ ATPase","novelty":"","modality":"Small molecule","drugClass":"","explanation":"Dexlansoprazole is the R-enantiomer of lansoprazole. It inhibits the final step of gastric acid production by binding to and blocking the proton pump in the stomach lining. The dual delayed-release formulation releases medication at two different pH levels, providing prolonged acid suppression throughout the day.","oneSentence":"Blocks the H+/K+ ATPase enzyme system (proton pump) in gastric parietal cells, suppressing gastric acid secretion.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123401,"model":"claude-sonnet-4-5-20250929"},"companyName":"Takeda","competitors":[{"name":"esomeprazole","brand":"Nexium","company":"AstraZeneca","rationale":"Proton pump inhibitor for GERD and erosive esophagitis"},{"name":"omeprazole","brand":"Prilosec","company":"AstraZeneca","rationale":"First-generation PPI for acid-related disorders"},{"name":"pantoprazole","brand":"Protonix","company":"Pfizer","rationale":"PPI indicated for GERD and erosive esophagitis"},{"name":"rabeprazole","brand":"AcipHex","company":"Eisai","rationale":"Proton pump inhibitor for GERD treatment"}],"description":"Dexlansoprazole is a proton pump inhibitor (PPI) developed by Takeda that reduces stomach acid production. It features a dual delayed-release formulation providing extended acid suppression. Used primarily for treating erosive esophagitis and gastroesophageal reflux disease (GERD) in adults.","genericName":"Dexlansoprazole Delayed Release Capsules","indications":{"approved":[{"status":"approved","condition":"Erosive esophagitis","patientPopulation":"Adults, healing and maintenance"},{"status":"approved","condition":"Symptomatic non-erosive gastroesophageal reflux disease (GERD)","patientPopulation":"Adults"},{"status":"approved","condition":"Heartburn associated with GERD","patientPopulation":"Adults"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}